Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting: Pooled analysis of 14 clinical trials

Supportive Care in Cancer

Volumn 6, Issue 5, 1998, Pages 473-478

  Whitmore, James B ^a   Kris, Mark G ^b   Hesketh, Paul J ^c   Grote, Thomas H ^d   DuBois, Dawn M ^e   Cramer, Michael B ^e   Hahne, William F ^f  

^a AMGEN INC   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c ST ELIZABETH'S MEDICAL CENTER   (United States)

^d Forsyth Hematology/Oncology   (United States)

^e SANOFI   (France)

^f EISAI INC   (United States)

Author keywords

Antiemetic; Chemotherapy induced nausea and vomiting; Cisplatin; Dolasetron mesilate

Indexed keywords

CISPLATIN; DOLASETRON MESILATE; SEROTONIN ANTAGONIST;

ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; QUINOLIZINES; VOMITING;

EID: 0031689252     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050197     Document Type: Article

References (38)

1. Audhuy B, Cappelaere P, Martin M, et al (1996) A double-blind, randomized comparison of the anti-emetic efficacy of two IV doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer [A] 32:807-813
2. Bertoli L, Yeilding A, Hankins J, et al (1992) Antiemetic dose finding study of a specific 5-hydroxytryptamine (5HT3) receptor antagonist (MDL 73,147EF) in patients receiving high dose cisplatin chemotherapy (abstract). Proc Am Soc Clin Oncol 11:395
3. Bots MWPG, Kijkstra HJ, Blijham GH, et al (1992) A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study. Neth J Med 40:221-226
4. Chevallier B, Cappelaere P, Splinter T, et al (1997) A double-blind, multicenter comparison of IV dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Support Care Cancer 5:22-30
5. Claybon L (1994) Single dose intravenous ondansetron for the 24 hour treatment of postoperative nausea and vomiting. Anaesthesia 49 [Suppl]:24-29
6. Cleri Baltzer L (1995) Serotonin antagonists: state of the art management of chemotherapy-induced emesis. Oncol Nurs 2:1-17
7. Conroy T, Cappelaere P, Fabbro M, et al (1994) Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonism in cancer patients treated with cisplatin. Am J Clin Oncol 17:97-102
8. Diemunsch P, d'Hollander A, Paxton L, et al (1997) Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery. J Clin Anesth 44:173-181
9. Diemunsch P, Leeser J, Feiss P, et al (1997) Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting. Can J Anaesth 44:173-181
10. Diemunsch P, Korttila K, Leeser P, et al (1998) Oral dolasetron mesylate for prevention of postoperative nausea and vomiting. J Clin Anesth 10:145-152
11. Fauser AA, Bleiberg H, Chevallier B, et al (1996) A double-blind, randomized, parallel study of intravenous dolasetron mesilate versus IV metoclopramide m patients receiving moderately emetosenic chemotherapy. Cancer 9:196-202
12. Fauser AA, Duclos B, Chemiassani A, et al (1996) Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer [A] 32:1523-1529
13. Garbe C, Drechsler S, Fiedler H, et al (1994) Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis. Semin Oncol 21:12-16
14. Graczyk SG, McKenzie R, Kallar S, et al (1997) Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery. Anesth Analg 84:325-330
15. Gralla RJ (1993) Current issues in the management of nausea and vomiting. Ann Oncol 4 [Suppl 3]:3-7
16. Grote TH, Pineda LF, Figlin RA, et al (1997) Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Cancer J Sci Am 3:45-51
17. Grunberg SM (1992) Phase I and other dose-ranging studies of ondansetron. Semin Oncol 19:16-22
18. Grunberg SM, Lane M, Lester EP, et al (1993) Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis. Cancer Chemother Pharmacol 32:268-272
19. Harman GS, Omura GA, Ryan K, Hainsworth JD, Cramer MB, Hahne WF (1996) A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 38:323-328
20. Hesketh PJ, Gandara DR (1991) Serotonin antagonists: as new class of antiemetic agents. J Natl Cancer Inst 83:613-620
21. Hesketh PJ, Gandara DR, Hesketh AM, et al (1996) Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer 4:141-146
22. Hesketh P, Navari R, Grote T, et al (1996) Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 14:2242-2249
23. Kovac A, McKenzie R, O'Connor T, et al (1992) Prophylactic intravenous ondansetron in female outpatients undergoing gynaecological surgery: a multicentre dose-comparison study. Eur J Anaesthesiol 9 [Suppl 6]:37-47
24. Kovac A, Chelly J, McKenzie R, Philip B, Pearman M, Brown R (1996) Multicenter intravenous dose-response trial to assess the efficacy and safety of dolasetron in preventing postoperative nausea and vomiting (abstract). Anesthesiology 85:A1
25. Kovac AL (1993) Use of serotonin receptor antagonists in the prevention of nausea and vomiting. Hosp Formulary 28:988-998
26. Kovac AL, Scuderi PE, Boerner TF, et al (1997) Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Anesth Analg 85:546-552
27. Korttila K, Clergue F, Feiss P. et al (1997) Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-bund, placebo-controlled study. Acta Anaesthesiol Scand 41:914-922
28. Kris MG, Grunberg SM, Gralla RJ, et al (1994) Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045-1049
29. Kris MG, Pendergrass KB, Navari RM, et al (1997) Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol 15:2135-2138
30. Markham A, Sorkin EM (1993) Ondansetron: an update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 45:931-952
31. Pendergrass K, Audhuy P, Hesketh P, et al (1996) Analysis of the optimal dose from eight pooled clinical trials assessing the acute antiemetic efficacy of intravenous dolasetron mesylate (DM) after emetogenic chemotherapy (ECT) (abstract). Proc ASCO 15:547
32. Plosker GL, Goa KL (1991) Granisetron: a review of its pharmacological properties and therapeutic use as an antiemetic. Drugs 42:805-824
33. Rubenstein EB, Gralla RJ, Hainsworth JD, et al (1997) Randomized, double blind dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Cancer 79:1216-1224
34. 3 antagonists in postoperative nausea and vomiting. Br J Anaesth 69 [Suppl 1]:63S-68S
35. Seynaeve C (1992) Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. Br J Cancer 66:192-197
36. Soukop M (1994) A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer 2:177-183
37. Van Belle SJ, Stamatakis H, Bleiberg H, et al (1994) Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting. Ann Oncol 5:821-825
38. Warriner CB, Knox D, Belo S, Cole C, Finnegan BA, Perreault L (1997) Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy. Can J Anaesth 44:1167-1173